Zovegalisib is currently being evaluated in ReDiscover, an ongoing first-in-human study, which was designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary ...
(MENAFN- GlobeNewsWire - Nasdaq) Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and median PFS in 2L patients Subset analyses show broad ...
Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with ...
CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
NEW YORK, September 03, 2025--(BUSINESS WIRE)--Rogo Technologies, Inc., the leading AI platform for investment banks, today announced the acquisition of Subset, an AI spreadsheet company backed by ...
However, details of the intervening steps, as researchers have learned in the past 65 years, are quite complex — certain cells carry the flu antigen to the immune system, specific immune cells respond ...
Every video game is a miracle. Long hours, extraordinary technical and artistic requirements and cross-disciplinary collaboration: the very act of making games is difficult, and leaves room for ...
During a Playdate Update livestream Thursday, Panic announced plans for a second season of games for its stylish black and white portable console with a crank — and those include a new game from ...
Camrelizumab addition to chemotherapy improved pCR rates by 12.2% in early or locally advanced TNBC patients compared to chemotherapy alone. Consistent pCR benefits were observed across subgroups, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback